Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors (PACAomics)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01692873|
Recruitment Status : Recruiting
First Posted : September 25, 2012
Last Update Posted : June 21, 2017
Pancreatic cancer is among the most serious human neoplasia and the most difficult to treat.
Most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month.
The aim of this study is the identification of diagnosis biomarkers, predictive of the therapeutic response.
This project investigate the use of molecular analyses applied to pancreatic tumor cells collected by microbiopsy under ultrasound-endoscopy, and blood cells.
|Condition or disease||Intervention/treatment|
|Pancreatic Tumor||Procedure: suspected pancreatic tumor|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Research for Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors - PACAomics / IPC 2011-004|
|Study Start Date :||February 2012|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2017|
Experimental: suspected pancreatic tumor
Realization of pancreatic tumor biopsy and blood samples
Procedure: suspected pancreatic tumor
Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
- Biomarkers [ Time Frame: within twenty four hours ]Genomics, transcriptomics and proteomics analyses to determine presence or absence of biomarkers
- Histology [ Time Frame: within twenty four hours ]To determine the histologic characteristics of the pancreatic tumor
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01692873
|Contact: Dominique GENRE, MD||33 (0)4 91 22 37 email@example.com|
|Contact: Agnès BOYER CHAMMARD, MD||33 (0)4 91 22 37 firstname.lastname@example.org|
|Marine GILABERT, MD||Recruiting|
|Marseille, France, 13009|
|Principal Investigator:||Marine GILABERT, MD||Institut Paoli-Calmettes|